Find a Research Study

The purpose of this study is to see how young athletes perform sport tasks and to see what movement patterns are related to future injury risk.

To investigate the connection between diet, genetics, and diseases in Hispanic / Latino youth.

To find out how SARS-CoV-2 is spread throughout a household.

The purpose of this study is to understand the impact of the COVID-19 pandemic on vulnerable families in Los Angeles, including those caring for a child with special health care needs. Information from this research will be used to understand what the key resource and service needs of families are at this time as well as identify interventions that can be developed or adapted to address these needs.

To improve patient care and achieve the best health outcomes possible for children with IBD.

The effect of flu immunization on the level of immunity against the flu in breastmilk, and how this may help protect a breastfeeding infant.

5,000 transgender women are testing a LifeSkills Mobile intervention web-app to see if it helps reduce condomless sex, increase PrEP use, and decrease HIV infections over several years.

To determine if MEDI8897 reduces the amount of visits to see a medical professional due to a lower respiratory tract infection caused by RSV. We will be looking at this in healthy preterm infants entering their first RSV session.

Data Collection only. By reviewing the charts of CAH infants who come to our facility for treatment, we hope to discover which treatments, all of which are standard of care, lead to better outcomes for patients (primarily in the first year of life).

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered twice daily (bid) with breakfast and evening meals for28 weeks in approximately 81 pediatric subjects with classic congenital adrenal hyperplasia (CAH) due to21-hydroxylase deficiency. Eligible subjects will be randomly assigned in a 2:1 ratio (active:placebo) to either crinecerfont (25 mg bid via oral solution for subjects 10 to <20 kg, 50 mg bid via oral solution for subjects 20 to <55 kg, or 100 mg bid via oral capsules for subjects ≥55 kg) or matching placebo (oral solution placebo for subjects <55 kg and oral capsule placebo for subjects ≥55 kg). Dose assignment from Day 1 to Week 28 will be based on the subject’s weight at Day 1. After the 28-week placebo-controlled treatment period, there will be a 24-week, open-label treatment period, during which all subjects will receive crinecerfont at doses based on their Week 28 body weight.